CSF1 and breast cancer: Previous studies have explored the use of selective monocyte-targeted chemotherapeutic agents, such as trabectedin or CSF1 inhibitors, to inhibit TAMs and reduce their infiltration in BC xenograft mouse models, leading to prolonged survival.